Hangzhou Mandy Biotechnology
Tirzepatide
Finnrick tested 7 samples of Tirzepatide (GLP-1 and GIP agonist) from Hangzhou Mandy Biotechnology between 25 Nov 2025 and 4 Mar 2026. Test scores average over 5, no score below 4, and at least 6 tests warrant a confident Finnrick Rating of C (Okay).
Finnrick Rating™
Hangzhou Mandy Biotechnology
Tirzepatide
Tested 7 Samples
Last test 4 Mar 2026
Take Action
Researcher
Request Full Data Access to the Finnrick database of peptide tests.
Free peptide testing
Mail in a sample (US only) to get confidence for the specific vials you have, and contribute to identifying unsafe supply chains, so other people can avoid risky and costly mistakes.
Other Tirzepatide tests from top-rated vendors:
All Tirzepatide tests from Hangzhou Mandy Biotechnology
Samples are tested in commercial labs
Tests Count
7
Scores
AVGMINMAX
Last
4 Mar 2026
First
25 Nov 2025
| Quantity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Test Date | Certificate | Test Score | Label | Tested | Difference | Purity | Endotoxins | Batch ID | Container | Tested At | Sent By |
| 4 Mar 2026 | View | 10mg | 10.2mg | +2.0% | 98.31% | n/a | (no batch ID) | No Label / Silver Crimp / Yellow Cap | Lab E | Public | |
| 26 Feb 2026 | View | 30mg | 31.4mg | +4.7% | 93.01% | n/a | (no batch ID) | No Label / Silver Crimp / Black Cap | Lab E | Public | |
| 13 Feb 2026 | View | 10mg | 9.55mg | -4.5% | 99.80% | below LOQ | (no batch ID) | No Label / Silver Crimp / White Cap | Lab E | Public | |
| 15 Jan 2026 | View | 30mg | 34.9mg | +16.3% | 99.80% | n/a | (no batch ID) | No Label / Silver Crimp / Green Cap | Lab G | Public | |
| 15 Jan 2026 | View | 40mg | 50.6mg | +26.5% | 99.90% | n/a | (no batch ID) | White Label / Silver Crimp / Red Cap | Lab G | Public | |
| 1 Jan 2026 | View | 20mg | 22.6mg | +13.0% | 99.70% | n/a | MBTR20251117GRY | White Label / Silver Crimp / Gray Cap | Lab G | Public | |
| 25 Nov 2025 | View | 20mg | 20.7mg | +3.5% | 98.81% | n/a | (no batch ID) | No Label / Silver Crimp / Violet Cap | Lab E | Public | |